People with unstable housing are most likely to not complete treatment for hepatitis C virus (HCV), and patients whose primary insurance is Medicaid are less likely to return…
[mc4wp_form id="449"]
Pain can be a difficult byproduct of many treatments, including treatments for inflammatory bowel disease (IBD). Researchers from the New York University College of Dentistry and Queen’s University…
New research suggests pediatric appendicitis patients are more likely to suffer from an additional Clostridium difficile (C diff) infection (CDI). A team, led by Felix Orelaru, MD, St. Joseph…
Two widely used treatments for Crohn’s disease yield similar results in biologic-naïve patients. A team, led by Neeraj Narula, McMaster University Medical Centre, compared the efficacy and rapidity…
The US Food and Drug Administration (FDA) has granted De Novo clearance to the GI Genius device, an artificial intelligence (AI) endoscopy module to assist clinicians in colonoscopy…
For hepatocellular carcinoma (HCC) patients, sCD163 may not be a reliable diagnostic marker but it can predict tumor response to locoregional therapies, according to a paper published in…
While glecaprevir/pibrentasvir (GLE/PIB) treatment is proven safe and effective in adults and adolescents with chronic hepatitis c virus (HCV) infections, the data is fairly limited in children. A…
Researchers are touting a new targeted opioid that could treat the diseased tissues of patients with inflammatory bowel disease without yielding some of the harmful and painful side…
Despite changes that have been made during the coronavirus pandemic to manage acute severe ulcerative colitis, there seems to be low risk for COVID-19 infection post-hospitalization or severe…
Direct-acting antivirals (DAA) appear to be associated with the alleviation of symptoms of oral lichen planus (OLP) in patients with hepatitis C virus (HCV), but more research is…